Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition of Celgene
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: PR Newswire
NEW YORK, March 19, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), a stockholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company")(NYSE: BMY), today announced that it has issued an investor presentation opposing the Company's proposed merger with Celgene Corporation (the "Merger"), which it believes is ill-advised and not in the best interests of Bristol-Myers shareholders. Starboard also announced today that it has mailed definitive proxy materials and a BLUE proxy card in connection with the Company's Special Meeting of Shareholders scheduled to take place on April 12, 2019, at which Bristol-Myers shareholders will vote on the issuance of shares of Bristol-Myers common stock pursuant to the Merger.The investor presentation and definitive proxy materials are available for viewing at www.shareholdersforbristol.com.About Starboard Value LPStarboard Value LP is a New York-based investment adviser with a focused and differentiated f
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb: The Comeback Is Unfolding [Seeking Alpha]Seeking Alpha
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… [YahoYaho
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…Business Wire
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s DiseaseBusiness Wire
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 3/28/24 - Form DEFA14A
- 3/28/24 - Form DEF
- 3/28/24 - Form ARS
- BMY's page on the SEC website